If you are:
FDB Contraindicated or Not Recommended: FETAL DEATH/MORBIDITY W/USE IN 2ND & 3RD TRIMESTER, STOP WHEN PREGNANCY DETECTED
Possibly Safe: NOT RECOMMENDED IN PRE-ECLAMPSIA AND OTHER PREGNANCY-INDUCED HYPERTENSION.
Precaution: INSUFFICIENT HUMAN DATA, EXCRETED IN RATS
Precaution: LIMITED AMOUNTS EXCRETED WITH NO KNOWN ADVERSE EFFECTS IN INFANT.
An adult over 60:
management or monitoring precaution: Cardiovascular-Increased sensitivity to effects on blood pressure. Metabolic-more likely to develop hypokalemia or hypomagnesemia. Endocrine-May worsen glucose control in diabetics. Renal-Not effective with CrCL < 30mL/min.
Giving olmesartan-hydrochlorothiazide to a child under 12:
Severe Precaution: Potential risk of impaired renal development age <1 year. Not recommended.
management or monitoring precaution: No demonstrated efficacy established age < 6 years. Potential risk of impaired renal development age < 1 year.